Abstract:Neurofibrillary tangles (NFTs), consisting of aggregates of abnormally hyperphosphorylated tau, are indicated in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD). Although hyperphosphorylation of tau is thought to cause aggregation and dissociation of tau from microtubules, the molecular mechanisms underlying the regulation of tau phosphorylation are largely unknown. While the PI3K/Akt pathway has increasingly been shown to regulate multiple cellular events pertinent to AD pathogenesis, including β–amyloid metabolism and tau phosphorylation via GSK–3, potential functions of tumor suppressor PTEN in AD pathogenesis have not been explored. In our study, we explored the molecular mechanisms for regulation of tau phosphorylation by asking the question that if PTEN, a tumor suppressor in PI3K/Akt signaling pathway, can affect tau phosphorylation at Akt and GSK–3 phosphorylation sites and the consequential effects on tau aggregation and binding to microtubules. We examined the effects of PTEN on tau phosphorylation, its microtubule association and formation of aggregates. We cotransfected COS–7 cells with human tau and human wild–type or phosphatase activity null mutant PTEN. We evaluated PTEN's effects on tau phosphorylation by using phospho–tau specific antibodies. To assess PTEN's effects on tau aggregation and binding to microtubules, we performed filter–retardation assay to detect and compare tau aggregates in cultured cells in the presence of wild–type or mutant PTEN. In addition, we fractioned the cotransfected cells to detect and compare the cytosolic, microtubule–bound, membrane–bound and insoluble aggregated tau between cells expressing wild–type and the mutant PTEN. Moreover, we infected rat cortical primary neurons with Sindbis viruses expressing wild–type or the mutant PTEN to monitor neuronal growth. At last, we performed immunohistology to compare phospho–tau and PTEN levels between AD patient and non–AD brains. 1. PTEN affects tau phosphorylation at Akt and GSK–3 phosphorylation sites. 2. PTEN affects tau aggregation and binding to microtubules. 3. PTEN's effects on tau phosphorylation are partially through PIP3/Akt signaling pathway.

Dephosphorylation Passivates the Seeding Activity of Oligomeric Tau Derived From Alzheimer’s Brain

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Alzheimer's Disease Seeded Tau Forms Paired Helical Filaments Yet Lacks Seeding Potential

Tau Ubiquitination in Alzheimer's Disease

Overexpression Of Tau Proteins Antagonizes Amyloid-Beta-Potentiated Apoptosis Through Mitochondria-Caspase-3 Pathway In N2a Cells

Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles*

A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies

Uncovering the Effect of Ps202/pt205/ps208 Triple Phosphorylations on the Conformational Features of the Key Fragment G192-T212 of Tau Protein

Role of Microtubule-Associated Protein Tau Phosphorylation in Alzheimer’s Disease

O-GlcNAcylation Modulates the Self-Aggregation Ability of the Fourth Microtubule-Binding Repeat of Tau

Phosphorylation of Tau Antagonizes Apoptosis by Stabilizing Β-Catenin, a Mechanism Involved in Alzheimer's Neurodegeneration

Hyperphosphorylation Results in Tau Dysfunction in DNA Folding and Protection.

Phosphorylation of Tau R2 Repeat Destabilizes Its Binding to Microtubules: A Molecular Dynamics Simulation Study

O2-01-05

Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation.

Tau Protein Associated Inhibitors in Alzheimer Disease

Tau Acts in Concert With Kinase/Phosphatase Underlying Synaptic Dysfunction

Modulation of Tau Pathology in Alzheimer's Disease by Dietary Bioactive Compounds

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease